Real-world Safety of Concurrent Pembrolizumab and Radiotherapy in Triple-negative Breast Cancer
Adjuvant radiotherapy can be safely administered concurrently with pembrolizumab in TNBC patients without increasing radiation-related adverse events, supporting the continuation of systemic therapy in this high-risk population. Nevertheless, larger prospective studies are needed to assess long-term toxicity.
Authors
- Youlia Kirova (ORCID: https://orcid.org/0000-0002-1795-7509)
- Jean‐Yves Pierga (ORCID: https://orcid.org/0000-0002-2863-9995)
- Abdul R. Fakih
- Mariana Mirabel (ORCID: https://orcid.org/0000-0002-9969-8896)
- Sofiane Allali
- Pierre Loap (ORCID: https://orcid.org/0000-0001-8863-8110)
- Luc Cabel (ORCID: https://orcid.org/0000-0001-5515-9180)
- Kim Cao (ORCID: https://orcid.org/0000-0003-2475-1821)
Institutions
- Institut Curie (FR)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1097/coc.0000000000001236
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94